论文部分内容阅读
目的 :了解凋亡抑制基因 (Bcl 2 )、凋亡诱导基因 (Bax)在急性髓系白血病的表达及Bcl 2 /Bax比值与耐药关系。方法 :用免疫组织化学法检测Bcl 2、Bax抗原表达 ,细胞培养四氮唑蓝比色法 (MTT)药敏试验检测急性髓系白血病(AML)耐药的情况。结果 :AML患者Bcl 2高于正常对照组 ,Bax低于正常对照组 ,其Bcl 2 /Bax比值显著高于正常对照组(P <0 .0 1)。产生耐药组的病例Bcl 2 /Bax高于敏感组 (P <0 .0 5 ) ,Bcl 2 /Bax高比值患者化疗反应差 (P <0 .0 5 )。结论 :Bcl 2、Bax的异常表达在AML形成、发展和产生耐药起一定作用 ,检测Bcl 2、Bax比值对治疗药物选择、预后的判断有重要意义。
Objective: To investigate the expression of Bcl 2 and Bax in acute myeloid leukemia and the relationship between Bcl 2 / Bax and drug resistance. Methods: The expressions of Bcl-2 and Bax were detected by immunohistochemistry and the drug resistance of acute myeloid leukemia (AML) was detected by MTT assay. Results: The Bcl-2 in AML patients was higher than that in normal controls and Bax was lower than that in normal controls (P <0.01). Bcl 2 / Bax was higher in the drug-resistant group than in the susceptible group (P <0.05), and the patients with high Bcl 2 / Bax ratio had poor chemotherapy response (P <0.05). Conclusion: Abnormal expression of Bcl-2 and Bax plays an important role in the formation, development and drug resistance of AML. The detection of the ratio of Bcl-2 and Bax is of great significance for the selection of therapeutic drugs and prognosis.